Loading data for LTGO — first visit, this takes a few seconds.
Latigo Biotherapeutics In... (LTGO)
NasdaqGS: LTGO
· Real-Time Price · USD
20.00
+0.70 (3.63%)
At close: Aug 18, 2026, 3:59 PM
Latigo Biotherapeutics Inc. (LTGO) Stock Price, Analysis & Data
3.63% (1D)
| Bid | n/a |
| Market Cap | 1.2B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -111.18M |
| Beta | n/a |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -0.47 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 254,895 |
| Avg. Volume (20D) | 668,812 |
| Open | 19.17 |
| Previous Close | 19.30 |
| Day's Range | 19.00 - 20.05 |
| 52-Week Range | 17.22 - 22.47 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LTGO
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibito...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 2026
Employees 59
Stock Exchange NasdaqGS
Ticker Symbol LTGO
Website https://latigobio.com
Financial Performance
In 2025, Latigo Biotherapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -109.17M, an increase of 78.43%.
Financial Statements
